Targacept to Present at the 15th Annual BIO CEO & Investor Conference

  Targacept to Present at the 15th Annual BIO CEO & Investor Conference

BIO CEO & Investor Conference 2013

Business Wire

WINSTON-SALEM, N.C. -- February 4, 2013

Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company
developing novel NNR Therapeutics (TM), today announced that Dr. Stephen A.
Hill, President and ChiefExecutive Officer, is scheduled to present at the
15th Annual BIO CEO & Investor Conference at The Waldorf Astoria New York in
New York City on Monday, February 11, 2013 at 1:00 p.m. Eastern Time.

The presentation will be webcast and accessible from the Investor Relations
page of Targacept’s website, www.targacept.com. To ensure a timely connection
to the webcast, it is recommended that users register at least 15 minutes
prior to the scheduled start time. An archived version of the webcast will be
available for replay on the Investor Calendar section of the Investor
Relations page of Targacept’s website for at least two weeks following the
event.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics(TM)
for difficult-to-treat diseases and disorders of the nervous system. NNR
Therapeutics selectively modulate the activity of specific neuronal nicotinic
receptors, unique proteins that regulate vital biological functions that are
impaired in various disease states. Targacept’s clinical pipeline includes
multiple Phase 2 product candidates, all representing first-in-class
opportunities. Targacept leverages its scientific leadership diverse pipeline
to attract significant collaborations with global pharmaceutical companies.
For more information, please visit www.targacept.com.

TARGACEPT

Building Health, Restoring Independence^®

Contact:

Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
alan.musso@targacept.com
or
Linnden Communications
Michelle Linn, 508-362-3087
linnmich@comcast.net
 
Press spacebar to pause and continue. Press esc to stop.